CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 141 filers reported holding CLOVIS ONCOLOGY INC in Q3 2014. The put-call ratio across all filers is 0.44 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $1,000 | -98.0% | 559 | -98.0% | 0.00% | – |
Q2 2022 | $50,000 | -61.8% | 27,990 | -56.8% | 0.00% | – |
Q1 2022 | $131,000 | -24.7% | 64,724 | +0.6% | 0.00% | – |
Q4 2021 | $174,000 | -35.1% | 64,314 | +6.9% | 0.00% | – |
Q3 2021 | $268,000 | +17.5% | 60,188 | +53.4% | 0.00% | – |
Q2 2021 | $228,000 | +121.4% | 39,239 | +166.6% | 0.00% | – |
Q1 2021 | $103,000 | +47.1% | 14,721 | +1.5% | 0.00% | – |
Q4 2020 | $70,000 | -17.6% | 14,507 | 0.0% | 0.00% | – |
Q3 2020 | $85,000 | -23.4% | 14,507 | -12.0% | 0.00% | – |
Q2 2020 | $111,000 | +76.2% | 16,483 | +66.4% | 0.00% | – |
Q1 2020 | $63,000 | -74.4% | 9,907 | -57.9% | 0.00% | – |
Q4 2019 | $246,000 | +167.4% | 23,549 | +0.5% | 0.00% | – |
Q3 2019 | $92,000 | -71.6% | 23,424 | +7.2% | 0.00% | – |
Q2 2019 | $324,000 | -36.8% | 21,847 | +5.8% | 0.00% | – |
Q1 2019 | $513,000 | +39.4% | 20,655 | +1.0% | 0.00% | – |
Q4 2018 | $368,000 | -20.5% | 20,457 | +29.9% | 0.00% | – |
Q3 2018 | $463,000 | -35.3% | 15,746 | 0.0% | 0.00% | -100.0% |
Q2 2018 | $716,000 | -16.3% | 15,746 | -2.8% | 0.00% | 0.0% |
Q1 2018 | $855,000 | -34.9% | 16,197 | -16.1% | 0.00% | 0.0% |
Q4 2017 | $1,313,000 | -11.0% | 19,312 | +7.5% | 0.00% | 0.0% |
Q3 2017 | $1,476,000 | +1.0% | 17,962 | +14.5% | 0.00% | 0.0% |
Q2 2017 | $1,462,000 | +83.2% | 15,693 | +24.5% | 0.00% | 0.0% |
Q1 2017 | $798,000 | +56.5% | 12,603 | +9.4% | 0.00% | – |
Q4 2016 | $510,000 | +77.1% | 11,516 | +39.9% | 0.00% | – |
Q3 2016 | $288,000 | +144.1% | 8,231 | -3.0% | 0.00% | – |
Q2 2016 | $118,000 | -28.0% | 8,483 | 0.0% | 0.00% | – |
Q1 2016 | $164,000 | -11.8% | 8,483 | +56.8% | 0.00% | – |
Q4 2015 | $186,000 | -61.0% | 5,411 | +5.0% | 0.00% | -100.0% |
Q3 2015 | $477,000 | +20.2% | 5,155 | +11.8% | 0.00% | – |
Q2 2015 | $397,000 | +14.4% | 4,610 | 0.0% | 0.00% | – |
Q1 2015 | $347,000 | +66.0% | 4,610 | +25.0% | 0.00% | – |
Q4 2014 | $209,000 | +17.4% | 3,687 | -2.3% | 0.00% | – |
Q3 2014 | $178,000 | – | 3,774 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 407,416 | $14,259,560,000 | 8.34% |
Palo Alto Investors LP | 3,547,719 | $124,170,000 | 6.91% |
Antipodean Advisors LLC | 1,268,658 | $44,403,000 | 6.48% |
Redmile Group, LLC | 1,795,936 | $62,858,000 | 4.70% |
HealthCor Management, L.P. | 1,525,000 | $53,375,000 | 3.24% |
PointState Capital LP | 3,503,900 | $122,637,000 | 3.12% |
NEA Management Company, LLC | 1,139,890 | $39,896,000 | 2.54% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 612,500 | $21,438,000 | 2.44% |
PFM Health Sciences, LP | 2,078,440 | $72,745,000 | 2.21% |
Partner Investment Management, L.P. | 35,300 | $1,236,000 | 2.03% |